AI-based digital sleep solution, dayzz, challenges traditional sleep treatment model following a Carmel Hospital pilot study showing an increase of 30 minutes sleep time by users.
dayzz is undoubtedly breaking boundaries as a treatment for insomnia, with a recent pilot study conducted by Carmel Hospital further substantiating this claim. According to the study, which was funded through the Israeli Innovation Authority, dayzz boosts CPAP use by 30 minutes nightly, challenging the traditional sleep treatment models by developing an innovative science-based approach and streamlining the treatment process for CPAP users.
“dayzz’s innovative sleep solution is revolutionary for CPAP users,” says Professor Giora Pillar, Director of the Sleep Disorder Clinic at Carmel Hospital. “By enhancing traditional sleep treatment with remote digital care, patients are actually able to get the comprehensive treatment and ongoing support they need for their sleep disorder. It is a true collaboration between healthcare organizations such as ours and tech innovation, placing the patient and their needs in the center.”
Amir Inditzky and his team are looking to help more people across the globe with the introduction of dayzz, an AI-based end-to-end digital sleep solution. The study conducted in partnership with Carmel Hospital’s Sleep Disorder Center, led by Professor Giora Pillar, revealed that people who used the dayzz app saw an increase in their nightly CPAP use by an average of 30 minutes per night.
“Beyond the incorporation of an innovative digital solution as a first line of sleep support within the traditional healthcare system, the collaboration revealed some unique opportunities to improve the efficiency and efficacy of the current sleep care journey,” says Dr. Mairav Cohen-Zion, Chief Science Officer at dayzz. “This unique pilot study emphasized that embedding digital-based solutions in traditional healthcare can provide not only significant value to patients and increased accessibility but also significantly reduce the burden on the healthcare system and enable streamlined processes.”
dayzz enables boosting CPAP use at home, reducing the burden of high-touch sleep apnea management on the healthcare system and giving patients a better experience. The launch of the solution is particularly timely, as OSA remains one of the most common sleep disorders, with an estimated 54 million American adults suffering from mild to severe forms of OSA. Consequently, millions of people in America and other parts of the world are severely impacted in their mood and energy levels, family functioning, work performance, and quality of life. Continuous Airway Pressure (CPAP) therapy is one of the best treatments for OSA. However, 30 to 60 percent of patients fail to use the device, which is where dayzz aims to make a difference.
The dayzz app is easily integrated into the lives of patients, leveraging data from wearables, smartphone sensors, and connected devices to make remote sleep care more accessible and efficient. Using dayzz helps to reduce the burden on the patient to input important data while enabling constant adjustments of the treatment plan based on the user’s treatment progress and personal data. The app is also designed to empower patients to set their own pace, adding a higher level of personalization, making patients more likely to adhere to a sleep plan, and boosting the chances of treatment success.
For further information about dayzz and how to leverage its features and functionality, visit – https://www.dayzz.com/. dayzz can also be found across social media, including Twitter and LinkedIn.
dayzz is an innovative app based on real scientific research that provides end-to-end sleep solutions for many sleep problems. Through its mobile app powered by AI along with human sleep trainers, device integration, and supporting content, including reports, dayzz is a one-stop shop enabling individuals to find the best solution for their sleep problems and allows organizations to promote healthier and more productive work environment for their employees.